Session » (2141–2176) RA – Treatments Poster III

Date: Tuesday, November 14, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

9:00AM-11:00AM: Abstract Number: 2167

24-week, Post-Marketing Surveillance Analysis of Upadacitinib in Japanese Patients with Rheumatoid Arthritis (Encore1)

9:00AM-11:00AM: Abstract Number: 2142

Adherence Patterns in Rheumatoid Arthritis Patients Receiving a Janus Kinase (JAK) Inhibitor or a Tumor Necrosis Factor α Inhibitor (TNFi) After the Addition of a Black Box Warning to JAK Inhibitors

9:00AM-11:00AM: Abstract Number: 2146

After JAK Inhibitor Failure, “Switching” or “Cycling”?

9:00AM-11:00AM: Abstract Number: 2149

Biologic IRL201805 Drives Differential Cell-contact and Metabolism Transcriptional Profiles in Monocytes from RA Patients Compared to Healthy Donors

9:00AM-11:00AM: Abstract Number: 2176

Cellular and Proteomic Changes Following Administration of Peresolimab, in a Phase 2a Trial in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2171

Common IL-6 Signaling Is Inhibited by IL-6 Inhibitors and JAK Inhibitors, but Which Is Better at Preventing Bone Destruction in RA?

9:00AM-11:00AM: Abstract Number: 2158

Continued Nintedanib Treatment in Patients with Progressive Pulmonary Fibrosis Related to Autoimmune Disease: Data from INBUILD-ON

9:00AM-11:00AM: Abstract Number: 2169

Cost-utility of a Progressive Spacing of Tocilizumab or Abatacept in Patients with Rheumatoid Arthritis in Sustained Remission: A Medico-economic Analysis of the Towards the Lowest Efficacious Dose Trial

9:00AM-11:00AM: Abstract Number: 2148

Do High RF Titers Impact Response to TNF Inhibitors? Comparison of Certolizumab Pegol and Adalimumab in Patients with RA and High Titers of RF: A Post Hoc Analysis of a Phase 4 Trial

9:00AM-11:00AM: Abstract Number: 2151

Effects of Methotrexate on Blood Pressure in Rheumatoid Arthritis: A Randomized Controlled Trial

9:00AM-11:00AM: Abstract Number: 2153

Effects of One-year Tofacitinib Therapy on Angiogenic Biomarkers in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2165

Efficacy of Abatacept in Rheumatoid Arthritis- associated Usual Interstitial Pneumonia. National Multicenter Study of 233 Patients During a Long-Term Follow Up

9:00AM-11:00AM: Abstract Number: 2143

Efficacy of Filgotinib in Patients with Rheumatoid Arthritis: Week 156 Results from a Long-term Extension Study

9:00AM-11:00AM: Abstract Number: 2156

Efficacy of Olokizumab in Comorbid Depressive Disorder in Patients with Rheumatoid Arthritis: Preliminary Results of a Study

9:00AM-11:00AM: Abstract Number: 2157

Exploratory Analysis of the Mechanisms of Action of the Potential Analgesic Effect of Tofacitinib and Adalimumab over Placebo in Patients with Rheumatoid Arthritis: Results of a Mediation Modeling Analysis

9:00AM-11:00AM: Abstract Number: 2141

Glucocorticoid Treatment in Early Rheumatoid Arthritis Is Associated with Increased Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) Levels: A Post-hoc Analysis of a Randomized Controlled Trial (NORD-STAR)

9:00AM-11:00AM: Abstract Number: 2174

JAK Inhibitors in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 73 Patients, 55 of Baricitinib

9:00AM-11:00AM: Abstract Number: 2166

Long-Term Effects of Abatacept on Arthritis and Atherosclerosis in Older vs Younger Patients with Rheumatoid Arthritis: 3-year Results of a Prospective, Multicenter, Observational Study

9:00AM-11:00AM: Abstract Number: 2150

Novel Biologic IRL201805 Inhibits Osteoclastogenesis in Monocytic Cells from RA Patients

9:00AM-11:00AM: Abstract Number: 2163

Omnipresent Poor Prognostic Factors in Early Rheumatoid Arthritis in the IMPROVED Trial; Is Earlier bDMARD Treatment Escalation for All Necessary?

9:00AM-11:00AM: Abstract Number: 2145

Patterns of Use, Effectiveness, Persistence and Cardiovascular Risk in Patients with Rheumatic Diseases Treated with Upadacitinib in a Real-world Setting. UPAREAL Study

9:00AM-11:00AM: Abstract Number: 2144

Pharmacodynamic Effects of Nipocalimab in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA): Results from the Multicenter, Randomized, Double-blinded, Placebo-controlled Phase 2A IRIS-RA Study

9:00AM-11:00AM: Abstract Number: 2161

Pharmacokinetic and Safety Similarity of High- and Low-Concentration Formulations of Adalimumab Biosimilar ABP 501

9:00AM-11:00AM: Abstract Number: 2160

Poly-Refractory Rheumatoid Arthritis: All B/tsDMARD Classes Exhausted – An Uncommon Disease Subset with Distinct Inflammatory and Non-inflammatory Phenotypes

9:00AM-11:00AM: Abstract Number: 2175

Real-World Drug Persistence of GP2015, an Etanercept Biosimilar, in Patients with Rheumatoid Arthritis: Results from the Multi-Country COMPACT Study

9:00AM-11:00AM: Abstract Number: 2164

Real-world Persistence of Initial Targeted Therapy Strategy in Monotherapy versus Combination Therapy in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 2159

Results of a 24-week Open-label, Non-interventional Study of the Efficacy and Safety of Olokizumab Therapy in Patients with Rheumatoid Arthritis After Switching from Anti-B-cell Therapy During the SARS-COV-2 Pandemic

9:00AM-11:00AM: Abstract Number: 2147

Safety and Effectiveness in Cycling Between Non-Selective and Selective JAKi in a Multi-Center Registry of Rheumatoid Arthritis in the Middle East

9:00AM-11:00AM: Abstract Number: 2162

Safety and Efficacy of Filgotinib: An Update from the DARWIN 3 Phase 2 Long-term Extension with a Maximum of 8.2 Years of Exposure

9:00AM-11:00AM: Abstract Number: 2172

Subcutaneus vs Intravenous Abatacept in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 509 Patients

9:00AM-11:00AM: Abstract Number: 2152

Survival Benefits of Knee and Hip Arthroplasty in Patients with Rheumatoid Arthritis: A General Population-based Cohort Study

9:00AM-11:00AM: Abstract Number: 2170

Systemic Glucocorticoids Are Associated with a Time and Dose-dependent Risk of Major Adverse Cardiovascular Event in Patients with Rheumatoid Arthritis: A Population-based Study

9:00AM-11:00AM: Abstract Number: 2155

The Impact of Filgotinib on Disease Activity Outcomes with Concomitant Pain Control in the Phase 3 FINCH Studies

9:00AM-11:00AM: Abstract Number: 2168

The Potential of Autologous Patient-derived Circulating Extracellular Vesicles to Improve Drug Delivery in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2154

Two-Year Persistence of First-Line Biological or JAK Inhibitor Treatment in Patients with Long-Standing Rheumatoid Arthritis and Failure of Triple Therapy with Synthetic DMARDs

9:00AM-11:00AM: Abstract Number: 2173

Window of Opportunity in the Treatment of Rheumatoid Arthritis-Interstitial Lung Disease with Abatacept. National Multicenter Study of 509 Patients

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].